Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING Platform
Tessera Therapeutics has secured over $300 million in Series C financing to advance its GENE WRITING technology aimed at curing genetic diseases. Investors include the Abu Dhabi Investment Authority and Alaska Permanent Fund Corporation. CEO Geoffrey von Maltzahn emphasizes the transformative potential of genetic medicine. The GENE WRITING platform enables precise modifications to DNA, unlocking new treatment possibilities for various conditions. Tessera's innovative approach positions it to potentially lead a new category in genetic medicine.
- Raised over $300 million in Series C financing to enhance GENE WRITING platforms.
- Strong investor backing from prestigious entities such as Abu Dhabi Investment Authority and Alaska Permanent Fund Corporation.
- Potential to revolutionize treatment for genetic diseases and other serious conditions.
- None.
Latest Financing Round Will Support Tessera’s Build Out of its GENE WRITING Platforms and Pursuit of Multiple Therapeutic Programs for Clinical Development
“We are thankful for the support from our new partners and existing investors alike in this latest funding round. It is our belief that genetic medicine will be the most important next epoch in medicine—offering the ability to cure genetic diseases and to someday even prevent disease from occurring,” said
“While there have been many advancements in the area of genetic medicine over the past decade, Tessera’s GENE WRITING platform is charting an entirely new course—one that aims to revolutionize genetic medicine as we know it,” said
Tessera’s GENE WRITING technology is designed to cure disease by writing in the code of life. The GENE WRITING platform can change any base pair to any other, make small insertions or deletions, and write entire genes into the genome with delivery of only RNA. This unlocks the potential to cure nearly any genetic disease, create life-changing medicines for other serious conditions such as cancer, and prevent illnesses with curative, scalable, and easily administered genetic medicines that could become a new modality in human healthcare.
GENE WRITING technology is inspired by nature’s genome architects—Mobile Genetic Elements (MGEs)—to overcome the limitations of gene editing and gene therapies. MGEs evolved to write new sequences of DNA into the genome, in contrast to nucleases like CRISPR which evolved to destroy DNA. Therefore, MGEs offer the potential for immense impact in genetic medicine by writing short and long therapeutic sequences of DNA into human cells. Tessera has designed, built, and tested tens of thousands of engineered and synthetic MGEs to create programmable GENE WRITING systems that can write and rewrite the genome with high-efficiency, specificity, and fidelity.
“The Tessera team has developed a remarkable GENE WRITING platform that confers unique advantages over alternative genetic medicine technologies, including base editing, CRISPR, and gene therapies,” said Vali Barsan, M.D., of SoftBank Investment Advisers. “Having worked closely with the company over the past year, it’s hugely exciting to observe GENE WRITING catalyze a new category of genetic medicine.”
For more information on Tessera Therapeutics, including how GENE WRITING technology works, partnership opportunities, and job openings, please visit www.tesseratherapeutics.com.
About Tessera’s GENE WRITER Technology
Tessera’s
About Tessera Therapeutics
Tessera Therapeutics is pioneering GENE WRITING technology, which consists of multiple technology platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source. The GENE WRITING platform allows the correction of single nucleotides, the deletion or insertion of short sequences of DNA, and the writing of entire genes into the genome, offering the potential for a new category of genetic medicines with broad applications both in vivo and ex vivo. Tessera Therapeutics was founded by Flagship Pioneering in 2018, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability. For more information about Tessera, please visit www.tesseratherapeutics.com.
About Flagship Pioneering
Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its
View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005210/en/
Greg Tenor, gregory.tenor@salutemcomms.com
TesseraTeam@salutemcomms.com
Source: Tessera Therapeutics
FAQ
What is the recent financing for CDAK?
What technology is Tessera Therapeutics developing?
Who are the investors in Tessera's latest funding round?
How does Tessera's GENE WRITING technology work?
What is the significance of the $300 million funding for the stock symbol OMGA?
What does the funding mean for SANA stockholders?
